BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (Nasdaq: ARRY) announced new Phase 1 clinical data on its MEK inhibitor, ARRY-162, and its p38 inhibitor, ARRY-797. These results were presented at the Annual European Congress of Rheumatology (EULAR) in Barcelona, Spain, and at the International Association of Inflammation Societies’ (IAIS) 8th World Congress on Inflammation in Copenhagen, Denmark.
